ATE521357T1 - Verfahren zur behandlung von hepatitis - Google Patents

Verfahren zur behandlung von hepatitis

Info

Publication number
ATE521357T1
ATE521357T1 AT03728926T AT03728926T ATE521357T1 AT E521357 T1 ATE521357 T1 AT E521357T1 AT 03728926 T AT03728926 T AT 03728926T AT 03728926 T AT03728926 T AT 03728926T AT E521357 T1 ATE521357 T1 AT E521357T1
Authority
AT
Austria
Prior art keywords
treating hepatitis
patient
pharmaceutical composition
carbon monoxide
relates
Prior art date
Application number
AT03728926T
Other languages
English (en)
Inventor
Leo OTTERBEIN
Augustine Choi
Brian Zuckerbraun
Original Assignee
Univ Yale
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ Pittsburgh filed Critical Univ Yale
Application granted granted Critical
Publication of ATE521357T1 publication Critical patent/ATE521357T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Saccharide Compounds (AREA)
AT03728926T 2002-05-17 2003-05-16 Verfahren zur behandlung von hepatitis ATE521357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38152702P 2002-05-17 2002-05-17
PCT/US2003/015263 WO2003096977A2 (en) 2002-05-17 2003-05-16 Methods of treating hepatitis

Publications (1)

Publication Number Publication Date
ATE521357T1 true ATE521357T1 (de) 2011-09-15

Family

ID=29550139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03728926T ATE521357T1 (de) 2002-05-17 2003-05-16 Verfahren zur behandlung von hepatitis

Country Status (16)

Country Link
US (4) US20040052866A1 (de)
EP (1) EP1505990B1 (de)
JP (1) JP4549847B2 (de)
CN (1) CN1668314B (de)
AT (1) ATE521357T1 (de)
CA (1) CA2485465A1 (de)
DK (1) DK1505990T3 (de)
EA (1) EA200401525A1 (de)
ES (1) ES2372273T3 (de)
HR (1) HRP20041071A2 (de)
MX (1) MXPA04011426A (de)
NO (1) NO20045056L (de)
PL (1) PL205066B1 (de)
RS (1) RS99304A (de)
UA (1) UA83465C2 (de)
WO (1) WO2003096977A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
SK15942003A3 (sk) * 2001-06-21 2004-08-03 Beth Israel Deaconess Medical Center, Inc. Farmaceutická kompozícia s obsahom oxidu uhoľnatého zlepšujúca prežívanie alebo funkciu orgánov po transplantácii
EP2042181A1 (de) * 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Verwendung CO- freisetzender Substanzen zur Herstellung eines Medikaments für die Behandlung entzündlicher Erkrankungen
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003223562B2 (en) 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
HRP20040972A2 (en) 2002-04-15 2005-06-30 University Of Pittsburgh Of The Commonwealth Systeyale University Methods of treating ileus
DK1505990T3 (da) 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
PL374375A1 (en) * 2002-06-05 2005-10-17 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
MXPA05004924A (es) * 2002-11-07 2005-08-18 Univ Pittsburgh Tratamiento para shock hemorragico.
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20040218547A1 (en) 2003-04-30 2004-11-04 Rhodey William George Process modification to maximize benzene production
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
JPWO2007073006A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 細胞保護性を有するアミノ酸の増加誘導剤及び増加方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US20100086519A1 (en) * 2008-10-03 2010-04-08 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of Hepatitis C Infection With Metalloporphyrins
CN105214193B (zh) 2009-05-27 2017-11-17 马林克罗特医疗产品知识产权公司 用于药物递送调节装置的分度药物收容装置组件及分度药物递送系统
CA3130908A1 (en) 2009-06-30 2010-12-30 Mallinckrodt Hospital Products IP Limited Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2011002584A1 (en) * 2009-07-02 2011-01-06 The University Of Iowa Research Foundation Treatment of hepatitis c virus infections
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
CA2844660A1 (en) * 2011-08-09 2013-02-14 Leo E. Otterbein Methods of treating dna damage
JP6457749B2 (ja) * 2013-12-27 2019-01-23 ハウスウェルネスフーズ株式会社 Ｖｃａｍ−１発現抑制剤
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
CN108057032B (zh) * 2018-01-30 2020-06-05 中国人民解放军第二军医大学第二附属医院 阿尔维林在制备预防或治疗门脉高压症的药物中的应用
EP3524290A1 (de) * 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Verfahren und system zur überwachung der kohlenmonoxid(co)-verabreichung an ex-vivo-flüssigkeiten

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
JP3746293B2 (ja) * 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
AU6523194A (en) 1993-03-26 1994-10-24 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
JP3195363B2 (ja) * 1995-06-30 2001-08-06 ザイモジェネティクス，インコーポレイティド Ｐｄｇｆアンタゴニストとしての４−〔２−（ｎ−２−カルボキサミドインドール）アミノエチル〕ベンゼンスルホンアミドまたはスルホニル尿素
US5702325A (en) 1996-01-30 1997-12-30 Icon Health & Fitness, Inc. Cabinet treadmill with handle
ES2190467T3 (es) * 1996-02-27 2003-08-01 Koster Henk W Sistema de respiracion con un modulo de administracion de gas adicional.
ATE331505T1 (de) * 1996-04-05 2006-07-15 Gen Hospital Corp Behandlung einer hämoglobinstörung
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
ES2210585T3 (es) 1996-08-27 2004-07-01 Messer Griesheim Gmbh Medicamento que contiene hidrogeno.
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
PT951292E (pt) * 1996-09-27 2007-06-18 Univ Columbia Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral.
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US5876604A (en) * 1996-10-24 1999-03-02 Compact Membrane Systems, Inc Method of gasifying or degasifying a liquid
US20010006973A1 (en) 1998-03-16 2001-07-05 Hon-Wah Man 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
JP2004526739A (ja) * 2001-03-30 2004-09-02 サングスタット メディカル コーポレイション 血管の、炎症性の及び免疫の障害の治療のための、一酸化炭素生成性化合物
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7122027B2 (en) * 2001-05-25 2006-10-17 Medtronic, Inc. Implantable medical device with controllable gaseous agent release system
SK15942003A3 (sk) * 2001-06-21 2004-08-03 Beth Israel Deaconess Medical Center, Inc. Farmaceutická kompozícia s obsahom oxidu uhoľnatého zlepšujúca prežívanie alebo funkciu orgánov po transplantácii
US7174178B2 (en) 2001-07-19 2007-02-06 Intel Corporation Deriving a more accurate estimate from prediction data in closed loop transmit diversity modes
EP2042181A1 (de) * 2002-02-04 2009-04-01 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Verwendung CO- freisetzender Substanzen zur Herstellung eines Medikaments für die Behandlung entzündlicher Erkrankungen
US7364757B2 (en) * 2002-02-13 2008-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating vascular disease
AU2003223562B2 (en) 2002-04-15 2009-04-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
HRP20040972A2 (en) 2002-04-15 2005-06-30 University Of Pittsburgh Of The Commonwealth Systeyale University Methods of treating ileus
KR20040106515A (ko) * 2002-05-09 2004-12-17 예일 유니버시티 바이오마커 및 치료제로서 일산화탄소
DK1505990T3 (da) 2002-05-17 2011-11-21 Univ Yale Fremgangsmåder til behandling af hepatitis
PL374375A1 (en) 2002-06-05 2005-10-17 Yale University Methods of treating angiogenesis, tumor growth, and metastasis
CA2490392A1 (en) * 2002-06-21 2003-12-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation
DE10230165A1 (de) 2002-07-04 2004-01-15 Ino Therapeutics Gmbh Verfahren und Vorrichtung zur Administration von Kohlenmonoxid
MXPA05004924A (es) 2002-11-07 2005-08-18 Univ Pittsburgh Tratamiento para shock hemorragico.
US20050255178A1 (en) 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
HRP20041071A2 (en) 2005-06-30
JP4549847B2 (ja) 2010-09-22
PL374177A1 (en) 2005-10-03
WO2003096977A2 (en) 2003-11-27
US20120276220A1 (en) 2012-11-01
EP1505990B1 (de) 2011-08-24
EA200401525A1 (ru) 2006-06-30
US20140141103A1 (en) 2014-05-22
DK1505990T3 (da) 2011-11-21
CN1668314B (zh) 2011-01-12
NO20045056L (no) 2005-02-16
JP2005533021A (ja) 2005-11-04
CA2485465A1 (en) 2003-11-27
MXPA04011426A (es) 2005-10-19
EP1505990A4 (de) 2008-02-20
UA83465C2 (uk) 2008-07-25
AU2003234585A1 (en) 2003-12-02
ES2372273T3 (es) 2012-01-17
US20130202720A1 (en) 2013-08-08
PL205066B1 (pl) 2010-03-31
US9522163B2 (en) 2016-12-20
CN1668314A (zh) 2005-09-14
EP1505990A2 (de) 2005-02-16
US20040052866A1 (en) 2004-03-18
WO2003096977A3 (en) 2004-03-11
RS99304A (sr) 2007-04-10

Similar Documents

Publication Publication Date Title
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
EA200401365A1 (ru) Способы лечения илеуса
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EA200401366A1 (ru) Способы лечения некротизирующего энтероколита
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
EA200401622A1 (ru) Способы лечения ангиогенеза, роста опухолей и метастазов
DE60306505D1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE435026T1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
ATE366579T1 (de) Verfahren zur behandlung von leberkrebs durch intrahepatische verabreichung von nemorubicin
ATE395055T1 (de) Pharmazeutische zusammensetzung zur behandlung von hyperhomocysteinämie
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
ATE454144T1 (de) Behandlung von malignen neoplasien

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties